Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared key takeaways and highlights from BTGLung2026 on X:
“Dr. Xiuning Le highlights the unmet needs for leptomeningeal disease in EGFR mutant NSCLC (and beyond) at BTGLung2026. In the modern era, we can see LMD in 11% of patients with EGFR NSCLC with incidence increasing with prolonged survival.
At BTGLung2026 ahead of WCLC26, Dr. Daniel Tan discusses the gaps in the 1L EGFR NSCLC space. Challenging selecting between available strategies. Can ctDNA be used for adaptive designs? Looking forward to results from the US SHEDDER study.
Dr. Solange Peters summarizes the state of immunotherapy for PD-L1+ early stage NSCLC with benefit seen across strata. Many open questions remain regarding biomarkers, accurate assessment of pCR, and how to assess and use MRD.
Nice summary of the blurring boundaries between two curative paradigms, surgery and radiation based, for locally advanced lung cancer by Kevin Chua at BTGLung2026 ahead of WCLC26. Choosing between both curative paradigms remains the evidence gap.
Review of open controversies with targeted thearpy in early stage NSCLC with Dr. Yilong Wu, Thomas Wu at BTGLung2026 ahead of WCLC26. Interesting discussion on importance of adjuvant chemotherapy when TKIs provide so much benefit – lots of selection, gaps in data.
Very nice overview of uncommon EGFR mutations and the now crowded exon 20 space from Dr. Tetsuya Mitsudomi at BTGLung2026. With so many variants that can impact biology, how do we best generate data. Functional databases, international registries, prospective real-world evidence?
Dr. Enriqueta Felip reviews all the ways in which MET contributes to NSCLC and can be targeted but many questions remain regarding optimal sequencing and combinations at BTGLung2026
Dr. Molly Li at BTGLung2026 highlights a burning question for HER2 mutant NSCLC – what is the optimal first line therapy? We now have zongertinib and sevabertinib approved as 1L TKIs and trastuzumab deruxtecan 1L study was positive, to be seen at WCLC26. How do we select?
BRAF V600E NSCLC is a unique subset of NSCLC that can respond well to targeted therapy but can also respond to immunotherapy, outlined by Dr. So Yeon Kim at BTGLung2026 ahead of WCLC26. Is there debate as to optimal first-line management?
Dr. David Planchard at BTGLung2026 discusses some of the current ADCs including those targeting TROP2. Clear efficacy, especially in EGFR NSCLC, but many data gaps regarding biomarkers, patient selection, mechanisms of resistance, CNS efficacy and in EGFR, alone or with TKI?
NRG1 fusions are rare but actionable alterations across cancer types, including NSCLC, outlined at BTGLung2026 by Dr. Stephanie Saw. Zenocutuzumab is a HER2/HER3 bispecific antibody approved in this setting. Given poor outcomes with standard therapy, should this be 1L?
Dr. Byoung Chul Cho summarizes some of the challenges in selecting treatment post immunotherapy at BTGLung2026. Novel agents hopefully coming but how do we select the right drug for each patient and can we still rebuild immunity with a potential for durable response?
Lots of discussion about tarlatamab and TCEs in SCLC at BTGLung2026 in session on ES-SCLC with Dr. Luis Paz-Ares. What will the barriers to implementation be? How will ADCs impact the first-line setting?
Good options for NSCLC with a RET fusion include selpercatinib and pralsetinib – how will the latest agent, lunbotinib, make an impact? Dr. Delvys Rodriguez Abreu outlines the field, highlights differences in toxicity, and stresses how important NGS is here.
Many new ADCs emerging but a real challenge, highlighted by Dr. Mihaela Aldea at BTGLung2026, is the commonalities specifically related to payload. Would we expect efficacy in sequencing these agents? Need to learn more about resistance and biomarkers to optimize use!
Dr. Martin Wermke at BTGLung2026 discusses SCLC and the unmet need. DLL3 seems to have some predictive power – can DLL3 expression on CTCs help with patient identification?
Dr. Benjamin Besse with an insightful perspective on ALK NSCLC at BTGLung2026. First-line strategies balance efficacy and safety – as landmark trials mature, the plateau in PFS is very impressive – at some point, progression becomes unlikely.
How will neladalkib change things?
Front-line immunotherapy data gaps include how to select patients for dual checkpoint inhibition, duration of therapy, role for emerging bispecifics and ADC combinations, biomarkers, possibility of lower doses. Very provocative summary from Dr.Lizza Hendriks at BTGLung2026.”
You can also read:
Sevabertinib Moves Into First-Line HER2-Mutant NSCLC With FDA Accelerated Approval
